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The existence of a cardiomyopathylike syndrome caused by 
persistent abnormal high heart rates is well documented ( I). 
Regression of cardiac dilation and symptoms of heart failure 
has been demonstrated after successful control of a variety 
of arrhythmias (I 2). Among patients at high risk for devel- 
oping heart failure are those who have tachycardia most of 
the day, patients with so-called incessant tachycardia. Al- 
though any tachycardia can become incessant, this is espe- 
cially common in patients who have a concealed accessory 
pathway with slow ventriculoatrial (VA) conduction (3-5). 
The arrhythmia may be present at birth and can be asym 
tomatic for a long time before heart failure develops. Often 
in patients with symptoms or signs of heart failure, or both, 
congestike cardiomyopathy is diagnosed and the tachycardia 
considered as a secondary atrial arrhythmia. The poor left 
ventricular function may then be considered a contraindica- 
tion to surgical treatment. In this study we examined 17 
patients with incessant supraventricular tachycardia to as- 
sess the effects of treatment on control of the arrhythmia and 
on symptoms and signs of heart failure. 
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uring an I P year period, 17 patients with 
supraventricular tachycardia COW- 
cealed accessory pathway with a long co were 
seen at our institution. incessant tachyc ed as 
the continuous presence of the arrhythmia; some interposed 
sinus beats could be recorded between the episodes. All 
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Figure 1. Patient 13. Typical electrocardiographic example of a 
circus movement tachycardia using a slowiy conducting accessory 
pathway for ventriculoatrial conduction. Note that the difference in 
rate of circus movement tachycardia before and during exercise is 
caused by a shortening of both the PR and the RP interval, 
demonstrating that the retrograde pathway is also sensitive to 
sympathetic stimulation. 
patients experienced incessant tachycardia while not receiv- 
ing drugs. A typical electrocardiographic example at rest and 
during exercise is shown in Figure I. The criteria used to 
diagnose the presence of the accessory pathway and its 
participation in the tachycardia have been described exten- 
sively (3.4). including differentiation from the “reversed” 
form of intranodal reentry (5) and from incessant atrial 
tachycardia (6-8). 
Hecrroplrysiologic study was performed in all patients in 
the postabsorptive nonsedated state after informed consent 
was obtained. The institutional committee on human re- 
search approved the study protocol. In summary, during the 
electrophysiologic study it was shown that a tachycardia 
circuit was present with atrioventricular (AV) conduction 
over the AV node and VA conduction over an accessory AV 
pathway with long conduction times. Endocavitary electro- 
grams recorded during incessant circus movement tachycar- 
dia are shown in Figure 2. 
racteristics (Table 1). Of the 17 patients, 7 had 
complaints of dyspnea and echocardiographic signs of a 
tachycardia-induced cardiomyopathy (group I ). In these 
seven patients a dilated heart as assessed echocardiograph- 
ically and the presence of dyspnea were considered to 
indicate cardiomyopathy. Of the remaining 10 patients with- 
out cardiomyopathy (group 2), three were in New York 
Heart Association functional class II (with normal cardiac 
dimensions on echocardiography) and seven in class 1. Of 17 
patients, 9 (7 from group I and 2 from group 2) ilot 
responded to previous antiarrhythmic drug therapy. Patient 
5 had undergone two unsuccessful sessions of direct current 
catheter ablation of the accessory pathway elsewhere. 
Surgical therapy, Of nine patients whose tachycardia 
could not be controlled by drug therapy, eight were treated 
surgically and one underwent successful direct current cath- 
eter ablation of the AV node. Of the eight patients who 
underwent surgery, two did not have symptoms or signs of 
cardiomyopathy. An endocardial approach, as reported by 
Sealy and Gallagher (9) was followed in five patients. The 
epicardial approach in the normothermic beating heart, as 
described by Guiraudon et al. (IO), was used in three 
patients. The division of the accessory pathway by means of 
surgery and direct current catheter ablation was successful 
in all patients, with no complications. 
Echorardiography. In six patients 
dimensional echocardiograms made before the procedure 
and afterward (at 2 weeks and at 24 months) were available 
for analysis. Left ventricular ejection fraction was assessed 
by planigraphy with the area-length method (1 I). Left ven- 
tricular end-diastolic (LVEDD) and end-systolic dimensions 
(LVESD) were calculated with the M-mode recording, in 
accordance with the recommendations of the American 
Society of Echocardiography (12). Fractional shortening was 
calculated as follows: IOO(LVEDD - LVESDYLVEDD. 
The only procedure to assess left ventricular function was 
echocardiography. Angiography was not considered justified 
in these patients. 
Statistical analysis. The paired or unpaired Student’s t 
test was used to analyze significant differences in heart 
function and dimensions before and 5.1 -C 3.7 weeks (range 
0.9 to 8.9) and 21.6 ? 6.8 months (range 14.5 to 32.4) after 
surgery or ablation. All values are expressed as mean values 
? SD. 
Clinical features (Tables 1 and 2). The group of 7 patients 
with tachycardia-induced cardiomyopathy were younger 
(mean age 23 ? I3 years) and had the arrhythmia diagnosed 
earlier in life (mean age at diagnosis 9 ? 9.8 years) compared 
with the IO patients without cardiomyopathy (mean age 39.7 
2 I4 and mean age at diagnosis 27.5 -C 20.3 years) (p < 0.05). 
The rate of circus movement tachycardia did not differ 
significantly between the two groups. Patients with signs or 
symptoms of cardiomyopathy had, on average, not re- 
sponded to treatemnt with more drugs. The only significant 
difference between the two groups in electrophysiologic 
variables was the HV interval (p c 0.001) (Table 2). 
JACC Vol. 96.9'90.3 
efore surgery or direct current catheter abltion, four 
patients were in functional class III for dyspnea, fo 
tients were in class 11 and one patient was in class 
follow-up a mean of 5.1 weeks after the procedure, seven 
patients were in functional c ass I an proved to class 
II. After a mean foilow-up interval r 6.8 months, 
eight patients were in functional c ass 1 and one was in class 
(p = NS) after 5.1 -C 3.9 weeks and to 58.6 9 8.0% (n = 5) 
(p = 0.002) after 21.6 f 6.8 months. 
The left ventricular end-diastolic diameter was 55.9 4 9.6 
~oced~re and decrease 
mm (n = 6) 5.1 weeks after the procedure (p 
49.0 + 3.4 mm (n = 5) (p = NS) after 21.6 months. 
ventricular end-systolic diameter similarly decreas 
.3 f 9.8 to 38.8 + 9.2 mm (n = 6) 4.8 weeks after surgery 
or ablation (p = NS) and to 32.2 f 2.9 mm (n = 5) after 21.6 
months (p = 0.009) (Fig. 3). No patient undergoing surgery 
or direct current catheter ablation received a~it~~hythmic 
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Table 1. Clinical Characteristics of 17 patients With Incessant Supraventricular Tachycardia and Tachycardia-Induced Cardiomyopathy 
(group I) or No Cardiomyopathy (group 2) 
NYHA Class 
Age at 
Age WV Diagnosis Before Early Late Current 
Pt. No. Gender (Yrl Procedure Follow-Up Follow-Up Medication Before Ablation Treatment 
Group I 
I* 27/F 2 III I I Amio + Dig 
2: 35/M 31 III I I Dig. Verap. Quin. Amio. Sotal. Enc 
3* 43/F I3 III I I Amio 
4% 32/F 3 II I I Proc. Ajm. Dig. Amio. Propaf 
5* II/F 4 II I I Dig t Amio, Propaf. Proc 
6* 20/F 7 II I I BB. Diso 
7* 12/F II III II I Amio. Dig 
Mean 23 9 
SD I3 9.8 
Group 2 
8 3fJF 35 I I I Sotal Verap 
9’ 54/F 25 II I I Dir: -I BB None 
IO 28/M I II I I Amio. Enc Amio + Propaf 
II* 19/M 0 I I I Verap None 
I2 49lF 34 II II II BB. Dig Dig + BB 
I3 19/M I I I I Amio Amio t Dig 
I4 48iM 46 I I I Sotal Sotal 
I5 50/M 49 I I I Dig t Amio Amio t BB 
I6 38/M 31 I I I BB. Enc Propaf 
I7 56/F 53 I - Diso Dead 
Mean 39.7 27.5 
SD I4 20.3 
*Underwent surgery: tunderwent direct current catheter ablation of atrioventricular node. Ajm = ajmaline: Amio = amiodarone, BB = be r-blocking agent; 
Dig = digoxin: Diso = disopyramide: Enc = encainide: F = female: M = male: NYHA = New York Heart Association functional class for dyspnea: Pt. = patient: 
Proc = procainamide: Propaf = propafenone: Quin = quinidine: Sotal = sotalol: Verap = verapamil. 
Table 2. Electrophysiologic Results in 17 Patients 
CMT Cycle 
Pt. No. Length RP PR HV RERP AVN 
Group I (tachycardia-induced cardiomyopathy1 
I 464) 330 130 
2 3 z 
4 320 
5 410 
6 520 
7 480 
Mean 424 
SD 59 
Group 2 (no cardiomyopathy) 
8 320 
9 420 
IO 470 
;I 490 2
I3 450 
I4 550 
I5 490 
lb 520 
17 510 
Mean 459 
SD 64 
260 140 
280 180 
200 120 
230 I90 
34tl 180 
280 I20 
- - 
270 
240 
320 
320 
300 
350 
380 
390 
340 
340 
- 
150 
180 
I50 
I70 
I20 
;z 
100 
I80 
170 
- 
;: ?!l 210 - 
90 320 280 
70 280 250 
:; 410 27 200 3 8
55 290 220 
63 303 243 
I4 52 40 
40 200 220 
:: 240 5 280 6
45 310 250 
35 240 220 
50 350 255 
45 310 240 
40 
40 ;: 
270 
230 
40 340 230 
43 282 245 
5 51 21 
All values are in milliseconds. AVN = anterograde refractory period of 
the atrioventricular node: CMT = circus movement tachycardia: Pt. = 
palient: RERP = retrograde refractory period of the accessory pathway; RP. 
PR. HV = electrocardiographic intervals. 
opathy (group 2). 7 were in functional class I and 3 in 
class 11 before treatment. Two patients underwent success- 
ful surgery and required no subsequent medication. One 
patient (Case 12) had incessant tachycardia and was in 
functional class 11; she had associated hyperthyroidism and 
diabetes that could have contributed to drug inefficacy. 
Patient I7 died of cancer in the same year that she had had 
her first evaluation. The other eight patients were well 
controlled with antiarrhythmic drugs (Table I) and in func- 
tional class 1. 
Value of the study. This study documents regression of a 
cardiomyopathylike syndronz after control of incessant 
supraventricular tachycardia caused by an accessory path- 
way with a long conduction time. As shown in patients with 
the Wolff-Parkinson-White syndrome (9, IO, l3-l5), surgical 
ablation of an accessory AV pathway can be achieved with 
a high success rate and minimal complications. The present 
study stresses the necessity of recognizing the arrhythmia as 
the cause of heart failure. 
Results of therapy. Of the I7 study patients, 8 were cured 
surgically And 1 underwent successful direct current catheter 
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Figutre 3. Patiernt 7. Three echocardiograms 
taken the day before surgery (A), on the 2nd 
postoperative day ( ) and 14 months afW 
surgery (SC). The improvement in left ven- 
tricular function is well demonstrated by 
comparing the left ventricular end-diastolic 
(LVEDD) and end-systolic (LVESD) di- 
mensions in panels A and Cc. 
ablation of the AV node. Definitive cessation of the inces- 
sant tachycardia was achieved in all 9 patients. 
Six patients from group 2 Illerc srcc.c.~~s~firli~ trcWed with 
antiarrhythmic drags (Table I). The decision to use one, two 
or no drugs was an empiric one. In these patients the 
incessant nature of the arrhythmia makes it Cguite easy to 
assess whether or not treatment is effective. 
~~~R~ca~ ~m~~~cat~o~s. There are several practical implica- 
tions of our observations: I) egression of the cardiomyop- 
atkylike syndrome after succ sful control of the arrhythmia 
s the existence of a tachycardia-induced 
cardiomyopathy 4 1.2). Recognition of such a cardiomyopa- 
thy is of crucial importance for successful control of the 
arrhythmia and heart failure. Differentiation from a true 
cardiomyo~tby with secondary atrial arrhythmias is weces- 
sary for the correct choice of treatment. 2) As exemplified by 
our patients, the presence of a tachycardia-induced cardio- 
myopathy is not a contraindication to surgery. On the 
contrary, in view of the excellent results in terms of cure of 
the arrhythmia and heart failure, surgery is mandatory when 
c~~rdiomyo~atby occurs as a conse uence of a surgical!! 
correctable incessant supraventricu r tachycardia. 3) Pi- 
nAly. given t&e results of surgery, it should be considered 
early in patients with an accessory pathway and incessant 
supraventricular tachycardia. If the ar~bythmia and tachy- 
cardia are difficult to control with antiarrhyt 
surgery should not be delayed until cardiomyopathy devel- 
ops. 
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